ストックスクリーナーアプリを入手
72.66
0.22%
-0.16
アフターアワーズ：
74.48
1.82
+2.50%
Halozyme Therapeutics Inc (HALO) 最新ニュース
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here’s Why - Yahoo Finance
US Stocks Recap: Why Halozyme Therapeutics Inc. stock could see breakout soon2025 Sector Review & Technical Pattern Based Buy Signals - BỘ NỘI VỤ
Take Profit: Is Halozyme Therapeutics Inc. stock positioned for digital transformationWeekly Trend Report & Smart Investment Allocation Tips - BỘ NỘI VỤ
United StatesCahill Represents Lead Arrangers In Halozyme Therapeutics’ $750 Million Credit Facility - Mondaq
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - PR Newswire
Halozyme Therapeutics announces CFO transition agreement with Nicole LaBrosse By Investing.com - Investing.com Nigeria
Halozyme Announces CFO Transition Plan - TipRanks
Halozyme Therapeutics announces CFO transition agreement with Nicole LaBrosse - Investing.com
[8-K] HALOZYME THERAPEUTICS, INC. Reports Material Event | HALO SEC FilingForm 8-K - Stock Titan
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View - MSN
Halozyme Acquires Drug Delivery Company Elektrofi - CHEManager
Quick ratio of Halozyme Therapeutics, Inc. – HAM:RV7 - TradingView
Is Halozyme Therapeutics Inc. (RV7) stock good for long term investingJuly 2025 PreEarnings & Precise Buy Zone Identification - newser.com
A Look at Halozyme Therapeutics (HALO) Valuation Following New Merus Collaboration and Expanded ENHANZE Platform Prospects - Yahoo Finance
Is Halozyme Therapeutics Inc. (RV7) stock nearing a technical breakoutJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Using Python tools to backtest Halozyme Therapeutics Inc. strategies2025 Stock Rankings & Real-Time Volume Triggers - newser.com
Why Halozyme Therapeutics Inc. stock is in analyst buy zone - newser.com
What Recent Analyst Upgrades and Partnerships Mean for Halozyme’s Evolving Story and Valuation - Yahoo Finance
Does the Latest Halozyme Partnership Signal Further Upside for the Stock in 2025? - Yahoo Finance
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
How strong dollar benefits Halozyme Therapeutics Inc. (RV7) stock2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesEarnings Risk Report & Low Risk Profit Maximizing Plans - newser.com
Will Halozyme Therapeutics Inc. stock see PE expansionJuly 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
Goldman Sachs Maintains Halozyme Therapeutics (HALO) Neutral Recommendation - MSN
Halozyme Therapeutics expands portfolio with Elektrofi acquisition - Traders Union
How Halozyme Therapeutics Inc. (RV7) stock performs in volatility spikesWeekly Trade Review & Detailed Earnings Play Alerts - newser.com
[S-8] HALOZYME THERAPEUTICS, INC. Employee Benefit Plan Registration | HALO SEC FilingForm S-8 - Stock Titan
What drives Halozyme Therapeutics Inc stock priceVolume Profile Analysis & High Return Capital Gain - earlytimes.in
Goldman Sachs Raises Price Target for Halozyme Therapeutics (HAL - GuruFocus
Halozyme Therapeutics Acquires Elektrofi for $750M - Contract Pharma
Halozyme Therapeutics Completes Elektrofi Acquisition - MarketScreener
Halozyme completes acquisition of Elektrofi for $750 million By Investing.com - Investing.com Nigeria
Halozyme completes acquisition of Elektrofi for $750 million - Investing.com
Halozyme completes acquisition of Elektrofi, expanding breadth of offerings in drug delivery - MarketScreener
Halozyme (NASDAQ: HALO) buys Elektrofi for $750M, targeting Hypercon royalties by 2030 - Stock Titan
Halozyme Therapeutics, Inc. completed the acquisition of Elektrofi, Inc. - MarketScreener
Merus and Halozyme partner on subcutaneous cancer drug delivery By Investing.com - Investing.com Nigeria
Halozyme stock price target raised to $56 from $54 at Goldman Sachs - Investing.com
Merus N.V. and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - MarketScreener
Merus, Halozyme Partner to Develop Subcutaneous Formulation of Petosemtamab - Contract Pharma
Merus and Halozyme link up on petosemtamab development - The Pharma Letter
Merus Licenses ENHANZE Drug Delivery Technology Of Halozyme Therapeutics - Nasdaq
Halozyme (HALO) Enters Collaboration Agreement with Merus - GuruFocus
Merus and Halozyme enter global collaboration and license agreement to develop subcutaneous formulation of Petosemtamab - MarketScreener
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - Merus
Merus and Halozyme partner on subcutaneous cancer drug delivery - Investing.com
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab – Company AnnouncementFT.com - Financial Times
Merus (MRUS) and Halozyme (HALO) license ENHANZE to develop subcutaneous petosemtamab - Stock Titan
Will Halozyme Therapeutics Inc. price bounce be sustainablePortfolio Performance Summary & Community Driven Trade Alerts - newser.com
0.76%
2.16%
大文字化:
|
ボリューム (24 時間):